Expression of BCL-2 and BAX-1 genes in the tissue of Ta T1 urothelial carcinoma and their prognostic value


Authors: Monika Szakácsová 1;  Viktor Soukup 1;  Marko Babjuk 2;  Jaroslav Mareš 3;  Jaroslava Dušková 4;  Tomáš Hanuš 1
Authors‘ workplace: Urologická klinika 1. LF UK a VFN, Praha 1;  Urologická klinika FN Motol a 2. LF UK, Praha 2;  Ústav biologie a lékařské genetiky 2. L F UK a FN Motol, Praha 3;  Ústav patologie 1. LF UK a VFN, Praha 4
Published in: Ces Urol 2013; 17(3): 204-209
Category: Original article

Overview

Aim:
The aim of this study was to evaluate the prognostic value of BCL-2 and BAX-1 gene expression in the tissue of non-muscle invasive superficial urothelial carcinoma.

Methods:
This study included 84 patients with Ta, T1 urothelial carcinoma of the bladder treated with transurethral resection. Mean follow-up was 23.64 months. Histopathological diagnosis of Ta was made in 48 patients, T1 in 36 patients, 23 patients were diagnosed with grade G1 tumor, 45 with grade G2 and 16 with grade G3. During the course of follow-up, tumor recurrence developed in 38 patients and progression was observed in 4 patients. The expression of BCL-2 and BAX-1 was examined using RT-PCR and determined using semi quantitatively. Gene glyceraldehyde-3-phosphodehydrogenasy (GAPDH) was used as the comparative gene.

Results:
Expression of BCL-2 was detected in 80 cases (95.2%) and the expression of BAX-1 in 72 cases (85.7%). The correlation between tumor recurrence and gene expression was not statistically significant. A statistically significant correlation was identified between the expression of BAX and grade of the tumor (p = 0.0459). The prognostic value of gene expression, with regard to disease progression, was not evaluated due to a small sample size.

Conclusions:
A significant correlation between the degree of BAX-1 expression and tumor grade was identified. No significant correlations were documented between gene expression and the other parameters studied.

Key words:
BAX-1, BCL-2, progression, recurrence, transitional cell carcinoma.


Sources

1. Uroweb.cz

2. Sylvester RJ, van der Meijden AP, Oosterlinck W, et al. Predicting recurrence and progression in individual patients with stage TaT1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 2006; 49(3): 466–465.

3. Soukup V, Babjuk M, Dušková J, et al. p53 pozitivita v nenádorové sliznici u pacientů s povrchovým uroteliálním karcinomem močového měchýře. Čas. Lék. čes. 2007; 146(1): 63–67.

4. Gazzaniga P, Gradilone A, Vercilo R, et al. BCL-2, BAX mRNA expression ratio as prognostic factor in low grade urinary bladder cancer. Int J Cancer 1996; 69: 100–104.

5. Sobin LH, Wittekind C. UICC TNM classification of malignant tumors. 6th ed. New York: Wiley-Liss 2002.

6. Mostofi FK, Sobin LH, Torloni H (eds.) International Classification of Tumors. Geneva: WHO 1973.

7. Kirch EJ, Baunoch DA, Stadler WM. Expression of bcl-2 and bcl-X in bladder cancer. J Urol, 1998; 159: 1348–1353.

8. Wu TT, Chen JH, Leech, Juany JK. The role of bcl-2, p53 and Ki-67 index in predicting tumour recurrence for low grade superficial transitional cell bladder carcinoma. J Urol 2000; 163: 758–760.

9. King ED, Matteson J, Jacobs SC, Kyprianou N. Incidence of apoptosis, cell proliferation and bcl-2 expression in transitional cell carcinoma of the bladder. Assotiation with tumour progression. J Urol 1996; 155: 316–320.

10. Esring D, Spruck CH, Nichols PW, Chaiwun B, Steven K, et al. P53 nuclear protein accumulation correlates with mutation in the p53 gene, tumor grade and stage in bladder cancor. Am J Pathol 1993; 143: 1289–1397.

11. Li B, Kanamaru H, Noriki S, Yamaguchi T, Fukuda M. Reciprocal expression of bcl-2 and p53 oncoproteins in urothelial dysplasia and carcinoma of the urinary bladder. Urol Res 1998; 26: 235–241.

12. Bilim V, Tomita Y, Kawasaki T, Katagiri A, Omak T, Takeda M, Takahashi K. Prognostic value of bcl-2 and p53 expression in urinary tract transitional cell cancor. J Natl Cancer Indy 1996; 88: 686–688.

13. Apte S, Matyek M, Olsen B. Mapping of the human BAX gene to chromosome 19q13.3-q13.4 and isolation of a novel alternatively spliced transcript BAX delta. Genomics 1995; 26: 592–594.

14. Korkolopoulou P, Lazaris Ach, Konstantinidou A, Kavantzas N, et al. Differential expression of bcl-2 family proteins in bladder carcinomas relationship with apoptotic rate and survival. Eur Urol 2002; 41: 274–283.

15. Gazzaniga P, Gradilone A, Giuliani L, Gandini O, Silvestri I, et al. Expression and prognostic significance of Livin, Survivin and other apoptosis related genes in the progression of superficial bladder cancer. Ann Oncol 2003; 14: 85–90.

16. Touloupidis S, Fatles G, Kalaitzis C et al. The significance of p53 and bcl-2 overexpression and other prognostic factors in transitional cell carcinoma of the bladder. Int Urol Nephrol 2006; 38(2): 231–236.

17. Stavropoulos NE, Filiadis I, Ioachim E, et al. Prognostic significance of p53, bcl-2 and Ki-67 in high risk superficial bladder cancer, Anticancer Res 2002; 22(6B): 3759–3764.

18. Lipponen PK, Aaltomaa S, Eskelier M. Expression of the apoptosis suppressing bcl-2 protein in transitional cell bladder tumors. Histopathology 1996; 28: 135–140.

19. Hussain SA, Ganesan R, Hiller L, et al. Proapoptotic genes BAX and CD40L are predictors of survival in transitional cell carcinoma of the bladder. Br J Cancer 2003; 88: 586–592.

Labels
Paediatric urologist Nephrology Urology
Login
Forgotten password

Don‘t have an account?  Create new account

Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account